News Headlines

  1. Minaris Expands Rapid Mycoplasma Detection Services With bioMérieux's BIOFIRE® Platform To Reduce Turnaround Time For Release And In-Process Testing 5/27/2026

    Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider, today announced an expanded rapid mycoplasma testing capability within its Minaris Advanced Testing division through the implementation of bioMérieux's BIOFIRE® Mycoplasma platform.

  2. CordenPharma Acquires AmbioPharm To Expand Global Peptide API Capacity 5/27/2026

    CordenPharma, a leading global Contract Development and Manufacturing Organization (CDMO), today announces that it has entered into an agreement to acquire AmbioPharm, a U.S.-headquartered peptide API CDMO.

  3. Olema Oncology Announces Clinical Trial Collaboration And Supply Agreement With Bayer To Evaluate OP-3136 In Combination With NUBEQA® (Darolutamide) In Metastatic Castration-Resistant Prostate Cancer 5/26/2026

    Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced a clinical trial collaboration and supply agreement with Bayer AG (“Bayer”) to evaluate OP-3136, Olema’s investigational lysine acetyltransferase 6 (KAT6) inhibitor, in combination with NUBEQA® (darolutamide), Bayer’s androgen receptor inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC).

  4. Adcendo ApS Announces Clinical Collaboration And Supply Agreement With MSD To Evaluate ADCE-T02 In Combination With KEYTRUDA® (Pembrolizumab) In A Phase Ib Study In Patients With Advanced Solid Tumors 5/26/2026

    Adcendo ApS ("Adcendo"), a biotech company focused on the development of first- and best-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need, today announced that it has entered into a clinical trial collaboration and supply agreement (the Agreement) with MSD (Merck & Co., Inc., Rahway, NJ, USA).

  5. Merz Therapeutics And Kvvit Enter Exclusive Agreement For INBRIJA® (Levodopa Inhalation Powder) In Mainland China, Hong Kong And Macao 5/26/2026

    Merz Therapeutics GmbH and Jiangxi Kvvit Pharmaceutical Co. Ltd. today announced that the companies have entered into an exclusive license and collaboration agreement regarding INBRIJA (levodopa inhalation powder) and its proprietary inhalation device for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor in mainland China, Hong Kong and Macao.​

  6. SK bioscience Signs Vaccine Technology Transfer Agreement With Colombia's VECOL To Advance Local Vaccine Manufacturing In Latin America 5/26/2026

    SK bioscience announced that it has signed an agreement with Colombia's state-owned pharmaceutical company VECOL for vaccine technology transfer and local manufacturing cooperation as part of Colombia's national vaccine localization initiative.

  7. Polpharma Biologics And Tuteur Sign Licensing Agreement For A Biosimilar For Autoimmune Diseases 5/22/2026

    Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur.

  8. Genethon And Ampersand Biomedicines Announce Partnership To Design Novel AAV Vectors With Enhanced Tissue Specificity For More Effective And Better Tolerated Gene Therapies 5/21/2026

    Genethon, the French pioneer in the discovery and development of gene therapies for rare diseases, and Ampersand Biomedicines, a Flagship Pioneering multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, announce an exclusive collaboration to engineer a new generation of AAV capsids with superior tissue specificity.

  9. Hanmi Pharmaceutical Partners With Organon To Export Combination Therapies To Southeast Asia 5/21/2026

    Hanmi Pharmaceutical announced that it has signed a supply agreement with global healthcare company Organon to export three combination medicines for the Malaysian and Philippine markets, expanding the companies’ partnership in Southeast Asia.

  10. 4basebio Signs Clinical Supply Agreement To Support Phase II Clinical Trial 5/20/2026

    4basebio PLC (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces that it has signed a Clinical Supply Agreement with a leading cancer immunotherapy innovator (“the Client”) to provide GMP-grade opDNA® starting material for its latest clinical programme.